"Interleukin-15" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cytokine that stimulates the proliferation of T-LYMPHOCYTES and shares biological activities with IL-2. IL-15 also can induce proliferation and differentiation of B-LYMPHOCYTES.
| Descriptor ID |
D019409
|
| MeSH Number(s) |
D12.644.276.374.465.515 D12.776.467.374.465.515 D23.529.374.465.515
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Interleukin-15".
Below are MeSH descriptors whose meaning is more specific than "Interleukin-15".
This graph shows the total number of publications written about "Interleukin-15" by people in this website by year, and whether "Interleukin-15" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2001 | 1 | 2 | 3 |
| 2002 | 2 | 0 | 2 |
| 2003 | 2 | 3 | 5 |
| 2004 | 2 | 3 | 5 |
| 2005 | 3 | 1 | 4 |
| 2006 | 1 | 2 | 3 |
| 2007 | 1 | 1 | 2 |
| 2008 | 3 | 2 | 5 |
| 2009 | 3 | 4 | 7 |
| 2010 | 3 | 0 | 3 |
| 2012 | 4 | 2 | 6 |
| 2013 | 1 | 4 | 5 |
| 2014 | 1 | 4 | 5 |
| 2015 | 1 | 2 | 3 |
| 2016 | 2 | 0 | 2 |
| 2017 | 2 | 2 | 4 |
| 2018 | 3 | 0 | 3 |
| 2019 | 3 | 1 | 4 |
| 2020 | 4 | 0 | 4 |
| 2021 | 5 | 2 | 7 |
| 2022 | 1 | 2 | 3 |
| 2023 | 1 | 4 | 5 |
| 2024 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Interleukin-15" by people in Profiles.
-
Anti-CD8/IL-15 (N72D)/sushi fusion protein: A promising strategy for improvement of cancer immunotherapy. Cytokine. 2025 Jan; 185:156822.
-
Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD. Cancer Cell. 2024 Aug 12; 42(8):1450-1466.e11.
-
Enhancing cancer immunotherapy with Anti-NKG2D/IL-15(N72D)/Sushi fusion protein: Targeting cytotoxic immune cells and boosting IL-15 efficacy. Cytokine. 2024 04; 176:156505.
-
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial. Nat Med. 2024 Mar; 30(3):772-784.
-
Generation of Non-Alloreactive Antiviral Central Memory CD8 Human Veto T Cells for Cell Therapy. Transplant Cell Ther. 2024 Jan; 30(1):71.e1-71.e13.
-
Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering. Sci Adv. 2023 07 28; 9(30):eadd6997.
-
Molecular mechanisms of snoRNA-IL-15 crosstalk in adipocyte lipolysis and NK cell rejuvenation. Cell Metab. 2023 08 08; 35(8):1457-1473.e13.
-
A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy. Blood Adv. 2023 06 13; 7(11):2479-2493.
-
IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM. J Immunother Cancer. 2023 02; 11(2).
-
Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15. Blood Adv. 2023 01 10; 7(1):9-19.